Protein / target

Alpha-2B adrenergic receptor

ADRA2BP18089Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
47
Approved medicines
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Alpha2-adrenergic receptor activity

Primary system

Cardiovascular system

Strongest disease association

migraine disorder

Genetic evidence · score 0.11

Therapeutic maturity

Clinically validated target

47 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Approved Drug

Clinical development

47 approved · 8 in clinical development

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression (PubMed:11056163, PubMed:2164221, PubMed:2172775, PubMed:23105096, PubMed:26811329). Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release (PubMed:2164221). The rank order of potency for agonists of ADRA2B is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol (PubMed:2164221, PubMed:2172775)

Subcellular location

Cell membrane
Domains and Gene Ontology detail (20)

Gene Ontology

  • Ccell surface
  • Cplasma membrane
  • Falpha2-adrenergic receptor activity
  • Fepinephrine binding
  • Padenylate cyclase-inhibiting adrenergic receptor signaling pathway
  • Padenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
  • Padrenergic receptor signaling pathway
  • Pcell-cell signaling
  • Pepidermal growth factor receptor signaling pathway
  • Pfemale pregnancy
  • PG protein-coupled receptor signaling pathway
  • Pnegative regulation of epinephrine secretion

450 aa · 50 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

G protein-coupled signallingUniProt · GOMuscle contractionGOKinase signallingGOHaemostasisGO
View supporting evidence

G protein-coupled signalling

  • ·Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that act…
  • ·adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
  • ·G protein-coupled receptor signaling pathway

Muscle contraction

  • ·positive regulation of uterine smooth muscle contraction
  • ·regulation of vascular associated smooth muscle contraction

Kinase signalling

  • ·positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction

Haemostasis

  • ·platelet activation
View underlying pathways (4)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

GNAQGNA11GNA13GNA12SEC24CGNB3ADRA2AGNB2GNB5GNB1ADRA2B

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Epinephrine
ApprovedAgonist

Adrenergic receptor agonist

Appears in clinical studies involving sudden cardiac arrest, asthma, sinusitis, septic shock

Acts on a complex — shared with ADRA1A, ADRA2A, ADRB2 +5 more · 1 of 9 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

migraine disorder0.11

Genetic · overall 0.59

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

major depressive disorder0.99

Clinical · overall 0.61

ocular hypertension0.99

Clinical · overall 0.60

attention deficit-hyperactivity disorder0.98

Clinical · overall 0.60

hypertensive disorder0.98

Clinical · overall 0.60

Nasal congestion0.98

Clinical · overall 0.60

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

open-angle glaucoma0.60

Clinical

glaucoma0.60

Clinical

asthma0.60

Clinical

seasonal allergic rhinitis0.59

Clinical

Show all associations
major depressive disorder0.61
hypertensive disorder0.60
ocular hypertension0.60
attention deficit-hyperactivity disorder0.60
Nasal congestion0.60
open-angle glaucoma0.60
glaucoma0.60
asthma0.60
seasonal allergic rhinitis0.59
migraine disorder0.59

Open Targets ranks 518 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 57 total

NOREPINEPHRINEApproval

cardiovascular disorder · Sepsis · major depressive disorder

ERGOTAMINE TARTRATEApproval

Headache · migraine disorder

LABETALOL HYDROCHLORIDEApproval

hypertensive disorder

ERGOTAMINEApproval

Headache · migraine disorder · orthostatic hypotension

PHENOXYBENZAMINEApproval

cardiovascular disorder · adrenal gland pheochromocytoma · hypoplastic left heart syndrome

LABETALOLApproval

cardiovascular disorder · Hypertension · preeclampsia

HYDROXYAMPHETAMINE HYDROBROMIDEApproval

Horner syndrome

METHYLDOPAApproval

hypertensive disorder · Hypertension · preeclampsia

EPHEDRINE HYDROCHLORIDEApproval

Nasal congestion · seasonal allergic rhinitis · common cold

METHYLDOPATE HYDROCHLORIDEApproval

Hypertension

Tractability

SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Small Molecule BinderOC · Approved Drug

Safety liabilities

skeletal muscle tremorincreased blood pressurecardiac ischemiadecreased survivalincreased heart failuredecreased blood pressureincreased heart ratedecreased painsedation

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

major depressive disorderModerately supported
0.75
agreement 0.590.90
Clinical99%Literature1%

Open Targets aggregate 0.61 · 2 independent evidence families

migraine disorderModerately supported
0.74
agreement 0.640.85
Clinical84%Genetic13%Literature3%

Open Targets aggregate 0.59 · 3 independent evidence families

hypertensive disorderModerately supported
0.74
agreement 0.590.90
Clinical97%Literature3%

Open Targets aggregate 0.60 · 2 independent evidence families

ocular hypertensionModerately supported
0.74
agreement 0.570.91
Clinical100%

Open Targets aggregate 0.60 · 1 independent evidence family

attention deficit-hyperactivity disorderModerately supported
0.74
agreement 0.580.89
Clinical99%Literature1%

Open Targets aggregate 0.60 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

12

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Label change2026-06-22

    Label change: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  2. Product recall2026-05-14

    Recall (Class III): EPINEPHRINE

    fda · safety · fda · via Epinephrine

  3. Regulatory approval2024-08-22

    Approval: Eurneffy (EMA)

    ema · regulatory · ema · via Epinephrine

  4. New publication2023-11-07
    Impact of norepinephrine on immunity and oxidative metabolism in sepsis.

    Frontiers in immunology · 2023 · 33 citations · Europe PMC · via Epinephrine

  5. Label change2023-01-05

    Label change: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  6. Supplemental approval2021-08-17

    Supplemental approval: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  7. New publication2019-10-31
    The effect of topical epinephrine 1:1000 with and without infiltration of 1% lidocaine with epinephrine 1:100,000 on endoscopic surgical field visualization: a double-blind randomized controlled study.

    International forum of allergy & rhinology · 2020 · 6 citations · Europe PMC · via Epinephrine

  8. Indication expanded2019-01-29

    Indication expansion: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  9. Label change2017-08-09

    Label change: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  10. Label change2016-05-18

    Label change: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  11. Supplemental approval2015-12-23

    Supplemental approval: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

  12. Regulatory approval2013-12-18

    Approval: EPINEPHRINE (NDA204640)

    fda · regulatory · fda · via Epinephrine

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.